Trials / Unknown
UnknownNCT01064557
"AIDA" Protocol (LAP 0493)
Guideline for the Treatment of Newly Diagnosed Patients Eith Acutypromyelocytic Leukemia, Aged > 12 Months (1 Year) and <75 Years, Using All-trans Retinoic Acid in Combination With Idarubicin
- Status
- Unknown
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 1,068 (estimated)
- Sponsor
- Gruppo Italiano Malattie EMatologiche dell'Adulto · Academic / Other
- Sex
- All
- Age
- 1 Year – 75 Years
- Healthy volunteers
- Not accepted
Summary
The main purposes of the AIDA protocol are to test the role of intermittent maintenance therapy with ATRA, standard maintenance chemotherapy with methotrexate and 6-mercaptopurine of both in PCR negative patients at the end of the consolidation phase and to evaluate the role of allogeneic or autologous bone marrow transplantation in PCR positive patients at the end of the consolidation phase.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | all-trans retinoic acid (ATRA) |
Timeline
- Start date
- 1993-10-01
- Primary completion
- 2020-12-01
- Completion
- 2020-12-01
- First posted
- 2010-02-08
- Last updated
- 2020-10-14
Locations
80 sites across 5 countries: Belgium, Germany, Italy, Netherlands, Turkey (Türkiye)
Source: ClinicalTrials.gov record NCT01064557. Inclusion in this directory is not an endorsement.